Sonoma Pharmaceuticals (SNOA) Total Current Liabilities (2016 - 2025)
Sonoma Pharmaceuticals has reported Total Current Liabilities over the past 15 years, most recently at $4.2 million for Q4 2025.
- For Q4 2025, Total Current Liabilities rose 13.88% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $4.2 million, up 13.88%, while the annual FY2025 figure was $4.1 million, 10.14% up from the prior year.
- Total Current Liabilities for Q4 2025 was $4.2 million at Sonoma Pharmaceuticals, down from $4.3 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $5.8 million in Q1 2022 and troughed at $3.1 million in Q4 2023.
- A 5-year average of $4.1 million and a median of $4.0 million in 2022 define the central range for Total Current Liabilities.
- Biggest five-year swings in Total Current Liabilities: soared 42.69% in 2022 and later crashed 36.12% in 2023.
- Year by year, Total Current Liabilities stood at $3.9 million in 2021, then increased by 1.52% to $3.9 million in 2022, then dropped by 21.86% to $3.1 million in 2023, then increased by 20.46% to $3.7 million in 2024, then grew by 13.88% to $4.2 million in 2025.
- Business Quant data shows Total Current Liabilities for SNOA at $4.2 million in Q4 2025, $4.3 million in Q3 2025, and $4.8 million in Q2 2025.